Protocol Ledger

NCT07082543 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Interventional Phase III clinical trial protocol NCT07082543 sponsored by Azafaros in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-30 Enrollment: 75 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07082543
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)75 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07082543
Protocol FieldVerified Registry Value
NCT IdentifierNCT07082543
Consolidated Lead SponsorAzafaros
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment75 participants (ESTIMATED)
Registered Start Date2025-06-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07082543
Hospital Research SiteLocationSite Profile
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI